Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 281-288

  Mallikaarjun, Suresh ^a   Kane, John M ^b   Bricmont, Patricia ^a   McQuade, Robert ^a   Carson, William ^a   Sanchez, Raymond ^a   Forbes, Robert A ^a   Fleischhacker, W Wolfgang ^c  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Aripiprazole once monthly; Pharmacokinetics; Safety; Tolerability

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LORAZEPAM; QUETIAPINE; RISPERIDONE; TEMAZEPAM; ZOLPIDEM TARTRATE;

ADULT; AKATHISIA; ANXIETY; AREA UNDER THE CURVE; ARTICLE; AUDITORY HALLUCINATION; BACKACHE; CLINICAL ARTICLE; COUGHING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; INJECTION SITE PAIN; INSOMNIA; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; MUSCLE STRAIN; MUSCULOSKELETAL STIFFNESS; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PSYCHOSIS; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; VOMITING;

ARIPIPRAZOLE ONCE-MONTHLY; PHARMACOKINETICS; SAFETY; TOLERABILITY;

ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOPHRENIA; TIME FACTORS;

EID: 84884151227     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.06.041     Document Type: Article

References (30)

1. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
2. Chue P., Eerdekens M., Augustyns I., Lachaux B., Molcan P., Eriksson L., Pretorius H., David A.S. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol. 2005, 15(1):111-117.
3. Fleischhacker W.W. Second-generation antipsychotic long-acting injections: systematic review. Br. J. Psychiatry Suppl. 2009, 52:S29-S36.
4. Fleischhacker W.W., Eerdekens M., Karcher K., Remington G., Llorca P.M., Chrzanowski W., Martin S., Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry 2003, 64(10):1250-1257.
5. Fleischhacker W.W., Sanchez R., Perry P.P., Jin N., Peters-Strickland T., Johnson B.R., Baker R.A., Eramo A., McQuade R.D., Carson W.H., Kane J.M. Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind, randomized. Non-inferiority Study vs. Oral Aripiprazole, 51st Annual Meeting of the American 2012, College of Neuropsychopharmacology (ACNP), Hollywood, FL, USA, (2-6 December).
6. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., Jeste D.V. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry 2004, 161(4):692-699.
7. Guy W. Abnormal Involuntary Movement Scale (AIMS), US Department of Health Education and Welfare. ECDEU Assessment Manual for Psychopharmacology 1976, 534-537. National Institute of Mental Health, Rockville, MD.
8. Guy W. ECDEU Assessment Manual for Psychopharmacology - Revised 1976, US Department of Health Services, Rockville, MD.
9. Hough D., Gopal S., Vijapurkar U., Lim P., Morozova M., Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 2010, 116(2-3):107-117.
10. Kane J.M. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J. Clin. Psychiatry 2006, 67(Suppl. 5):9-14.
11. Kane J.M., Eerdekens M., Lindenmayer J.-P., Keith S.J., Lesem M., Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003, 160(6):1125-1132.
12. Kane J.M., Detke H.C., Naber D., Sethuraman G., Lin D.Y., Bergstrom R.F., McDonnell D. Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am. J. Psychiatry 2010, 167(2):181-189.
13. Kane J., Sanchez R., Perry P., Jin N., Johnson B., Forbes R., McQuade R., Carson W., Fleischhacker W. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind placebo-controlled study. J. Clin. Psychiatry 2012, 73(5):617-624.
14. Kay S., Fiszbein A., Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
15. Lauriello J., Lambert T., Andersen S., Lin D., Taylor C., McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J. Clin. Psychiatry 2008, 69(5):790-799.
16. Lindenmayer J. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr. Dis. Treat. 2010, 6:261-267.
17. Mallikaarjun S., Salazar D.E., Bramer S.L. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharmacol. 2004, 44(2):179-187.
18. Mallikaarjun S., Shoaf S.E., Boulton D.W., Bramer S.L. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin. Pharmacokinet. 2008, 47(8):533-542.
19. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., Saha A., Ali M., Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 2003, 61(2-3):123-136.
20. McIntyre R.S., Soczynska J.K., Woldeyohannes H.O., Miranda A., Konarski J.Z. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert. Opin. Pharmacother. 2007, 8(7):1001-1009.
21. Nasrallah H.A. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr. Scand. 2007, 115(4):260-267.
22. Otsuka Pharmaceutical Co., Ltd. ABILIFY MAINTENA (aripiprazole) Prescribing Information. Tokyo, 101-8535, Japan February. Accessed at. http://www.otsuka-us.com/Products/Documents/Abilify.M.PI.pdf.
23. Potkin S.G., Raoufinia A., Mallikaarjun S., Bricmont P., Peters-Strickland T., Kasper W., Jin N., Baker R.A., Eramo A., Sanchez R., McQuade R.D. An open-label safety and tolerability study of once-monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on atypical oral antipsychotics other than aripiprazole. US Psychiatric and Mental Health Congress, San Diego, CA, USA 2012, (8-11 November).
24. Rauch A.S., Fleischhacker W.W. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS. Drugs 2013, Jun 19. (Electronic publication ahead of print).
25. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
26. Sparshatt A., Taylor D., Patel M.X., Kapur S. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J. Clin. Psychiatry 2010, 71(11):1447-1456.
27. Stip E., Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin. Ther. 2010, 32(Suppl. 1):S3-S20.
28. Valenstein M., Ganoczy D., McCarthy J.F., Myra Kim H., Lee T.A., Blow F.C. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J. Clin. Psychiatry 2006, 67(10):1542-1550.
29. Velligan D., Weiden P., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70(Suppl. 4):1-46.
30. Wiersma D., Wanderling J., Dragomirecka E., Ganev K., Harrison G., An Der Heiden W., Nienhuis F., Walsh D. Social disability in schizophrenia: its development and prediction over 15years in incidence cohorts in six European centres. Psychol. Med. 2000, 30:1155-1167.